Patent · US Active

Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP

US11208476B2 · kind B2 · utility

8Cited by

0References

12Claims

0Family size

Assignees

Ablynx N.V. · BE
Sanofi · FR

Inventors

Heidi Rommelaere · Wondelgem, BE
Ann Brigé · Ertvelde, BE
Sigrid Cornelis · Gent, BE
Bruno Dombrecht · Heusden, BE
Eric Lorent · Zwijnaarde, BE
Melanie Rieger · Zwijnaarde, BE
Timothy Soos · Boston, US
John Park · Warthausen, DE
Bernd Weigle · Ingelheim am Rhein, DE
Klaus Erb · Mittelbiberach, DE

Key dates

Filing date	Mar 22, 2021
Grant date	Dec 28, 2021
Priority date	—
Expiry date	Mar 22, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.